GBGB has received an unusually high number of positive samples relating to the non-steroidal anti-inflammatory drug, meloxicam. In collaboration with its designated laboratory LGC, GBGB is currently investigating the circumstances surrounding these positives and while it does so, all existing and future inquiries involving positive samples for meloxicam, will remain pending.